Cerity Partners
RLAY icon

Cerity Partners’s Relay Therapeutics RLAY Stock Holding History

Cerity Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385K Sell
20,601
-3,594
-15% -$52.2K ﹤0.01% 2612
2026
Q1 		$241K Buy
24,195
+3,149
+15% +$28.2K ﹤0.01% 2766
2025
Q4 		$178K Sell
21,046
-195
-0.9% -$1.39K ﹤0.01% 2666
2025
Q3 		$111K Buy
21,241
+6,408
+43% +$24.4K ﹤0.01% 2618
2025
Q2 		$51.3K Buy
+14,833
New +$44.1K ﹤0.01% 2545

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Cerity Partners's RLAY Position: Q2 2026 in Review

Cerity Partners reduced its Relay Therapeutics (RLAY) stake by 15% in Q2 2026, selling an estimated $52.2K and leaving 20,601 shares worth $385K. The position accounts for ﹤0.01% of the portfolio, ranked #2612.

Cerity Partners first reported a position in RLAY in Q2 2025 and has held it in 5 quarters since. 238 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Cerity Partners held 20,601 shares of Relay Therapeutics worth $385K as of Q2 2026.
  • Cerity Partners sold 3,594 Relay Therapeutics shares in Q2 2026, an estimated $52.2K.
  • Relay Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2612 holding.
  • Cerity Partners first reported a position in Relay Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 238 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.